



an onTargetjobs company

# Bio InvestorForum

OCTOBER 18-19, 2006 • SAN FRANCISCO

Showcasing the Leading  
Growth Companies  
in Life Sciences

Quick Search:

[Home](#)
[About BioSpace](#)
[News](#)
[Hotbed Communities](#)
[Career Center](#)
[Insight™](#)
[GenePool](#)

## BioSpace Beat

The Industry Today!

[Breaking News](#)  
[By Subject](#)  
[Archive](#)  
[BioBuzz](#)

**BioSpace - FREE Daily Newsletters!**  
GenePool, Career Insider, Clinical Focus and Deals & Dollars

**NEW! BioSpace Forum**  
A Community Discussion Board

**Hotbed Communities**  
Regional News, Info & Maps

- [Bio NC™](#)
- [BioCapital™](#)
- [BioMidwest™](#)
- [BioGarden™ \(NJ\)](#)
- [Biotech Bay™](#)
- [Biotech Beach™](#)
- [Genetown™](#)
- [Pharm Country™](#)
- [Southern Pharm™](#)

**Career Center**  
Discover Your Future

[For Job Seekers](#)  
[Search Jobs](#)  
[Post Resume](#)  
[Career Fairs](#)

[For Employers](#)  
[Post a Job](#)  
[Search Resumes](#)

**NEW! Medical Device & Diagnostics Channel**  
Industry News & Updates

**Diversity Channel**  
The Culture of Life Science

**BioPharm Insight**  
Investigational Drug Data  
Prescription Drug Forecasts  
Drug Licensing Deals

**BioZones**  
Building Blocks For Biotech

- [BioCrossroads™ \(IN\)](#)
- [Bio UK™](#)
- [Isla de Biotech™ \(PR\)](#)

**For Investors**  
Investment in Knowledge

[Newsletters](#)  
[Forums](#)  
[BioSpace Bellwethers](#)  
[Stocksort](#)  
[BioSpace Movers](#)  
[By Hotbed](#)  
[IPOs](#)  
[IPO News](#)  
[Deals & Dollars](#)  
[Clinical Development](#)  
[News](#)  
[Brokerage Ratings](#)  
[Personal Portfolio](#)  
[Venture Reports](#)

**Companies**  
Biotech Company Details

[Search Companies](#)  
[Suppliers](#)  
[Service Firms](#)

**Start-Ups**  
Track Newcomers in Biotech

[Start-Up Jobs](#)  
[Start-Up Companies](#)

October 06, 2006 03:51 PM Eastern Time

## CepTor Reports Two Issues Remain to Move Myodur IND Forward

### - FDA Instructs Company to Address Two Issues Before Granting Clearance to Begin Human Muscular Dystrophy Trials -

HUNT VALLEY, Md.--(BUSINESS WIRE)--**CepTor Corporation (OTC BB:CEPO)**, a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that its Investigational New Drug application (IND) for Myodur to be used in Duchenne muscular dystrophy trials remains on hold. In a teleconference with the FDA, the agency reported that there are two remaining issues that it would like the Company to address before moving into human trials. The Company reported that the remaining two items are straightforward and addressable.

#### About CepTor Corporation

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. CepTor's primary efforts are currently focused on moving its lead product, Myodur, into clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP) and amyotrophic lateral sclerosis (ALS). More information about CepTor can be found at [www.ceptorcorp.com](http://www.ceptorcorp.com).

*The press release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involves a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation on our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. The Company disclaims any obligation to update any forward-looking statement as a result of developments occurring after the date of this press release.*

#### Contacts

**CepTor Corporation**  
Donald W. Fallon, 410-527-9998  
Fax: 410-527-9867  
[dfallon@ceptorcorp.com](mailto:dfallon@ceptorcorp.com)  
or  
**Wolfe Axelrod Weinberger Assoc. LLC**  
Donald C. Weinberger, 212-370-4500  
Fax: 212-370-4505  
[don@wolfeaxelrod.com](mailto:don@wolfeaxelrod.com)  
or  
Media:  
Alisa D. Steinberg, 212-370-4500  
Fax: 212-370-4505  
[alisa@wolfeaxelrod.com](mailto:alisa@wolfeaxelrod.com)



**Leading  
the way in  
Lyophilization**



**Need to  
create  
efficiencies  
and  
streamline  
medical  
device  
development?**



[Biophotonics International](#)  
[Drug Discovery News](#)  
[BioTechniques](#)  
[Hundreds more titles...](#)

3rd Annual  
**Tumor  
Progression  
& Therapeutic  
Resistance**

October 22-24  
Baltimore, MD



[Start-Up Events](#)

[Terms of Use](#) | [© Business Wire 2006](#)

---

**Science Center**

Scientific Community Content

[Quick Lit Search](#)

**Industry Events**

Biotech Calendar Of Events

**MarketPlace**

A Buyers Guide To Biotech

**Resources**

Valuable Industry Information

[Real Estate](#)

**Customer Care**

BioSpace Contact Information

[BioPharm Insight](#)	[News](#)	[Career](#)	[Hotbeds](#)	[Companies](#)	[FREE Magazines](#)
[Investor](#)	[Start-Ups](#)	[Expert Search](#)	[Science Center](#)	[Events](#)	[Marketplace](#)
[Resources](#)	[Real Estate](#)	[Search](#)	[GenePool](#)	[Help](#)	[Home](#)

---

[Advertising Opportunities On BioSpace](#)  
[Sponsorship Opportunities On BioSpace](#)  
[BioSpace Information](#)

[Post a Job on BioSpace](#)  
[Post an Event on BioSpace](#)  
[Post your News on BioSpace](#)  
[Post a Company Profile on BioSpace](#)

---